Evidence map›Paper›PMID 35090034›Full record

ArticleNeuro-oncology2022

CD55, a potential immunotherapeutic target for MYCN-amplified neuroblastoma.

Hiroyuki Yoda, William A Weiss

Abstract readEditorialComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Hiroyuki YodaUCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, USA.
William A WeissUCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, USA.

Funding

Tissue CoreP50CA097257 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Joseph F Costello · 2002 to 2026
$57.4M
Tumor microenvironment-dependent therapy resistanceP01CA217959 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI Kimberly Stegmaier · 2017 to 2026
$20.7M
Mouse models to discover new drivers of medulloblastomaR01CA159859 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI Michael D. Taylor, WILLIAM A WEISS · 2011 to 2026
$10.4M
Integrating targeted and immunotherapy to treat genetically heterogeneous cancersU01CA217864 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BALMAIN, ALLAN, KRUMMEL, MATTHEW F · 2017 to 2021
$5.1M
CCL2 and CCR2 as metastatic drivers and therapeutic targets in medulloblastomaR01CA255369 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GARZIA, LIVIA, TAYLOR, MICHAEL D. · 2021 to 2025
$3.9M
Improving the efficacy of mTOR inhibitionR01CA221969 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FAN, QI WEN, SHOKAT, KEVAN M. · 2018 to 2022
$2.9M
Prevention and treatment of lethal metastases in group 3 medulloblastomaR01NS106155 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI TAYLOR, MICHAEL D., WEISS, WILLIAM A · 2018 to 2022
$2.8M
Inhibitors of the G protein GNAS which drives pancreatic tumorigenesisR01CA244550 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SHOKAT, KEVAN M. · 2020 to 2024
$2.0M
Cancer Research UK A28592NCI NIH HHS P01 CA217959NCI NIH HHS P50 CA097257NCI NIH HHS R01 CA159859NCI NIH HHS R01 CA221969NCI NIH HHS R01 CA244550NCI NIH HHS R01 CA255369NCI NIH HHS U01 CA217864NINDS NIH HHS R01 NS106155
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Human Embryonic Stem CellsNeuroblastomaHumansImmunotherapyNeoplastic Stem CellsNeural CrestN-Myc Proto-Oncogene ProteinTranscription FactorsMYCN protein, humanN-Myc Proto-Oncogene ProteinTranscription Factors

Identifiers

PMID35090034
PMCPMC9159426

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.